Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint
December 08, 2017 16:05 ET
|
Akari Therapeutics Plc
Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original dosing regimen. The Day 28 Endpoint was...
Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting
December 04, 2017 16:01 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
October 18, 2017 09:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares
October 17, 2017 16:01 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
Akari Therapeutics Announces Further Clinical Progress
October 11, 2017 07:00 ET
|
Akari Therapeutics, Plc
Completion of enrollment into COBALT, the Phase II PNH trial of Coversin™ NEW YORK and LONDON, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company...
Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
September 21, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to...
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive...
Akari Therapeutics Announces Appointment of David Horn Solomon as CEO
August 21, 2017 07:05 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX) is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive...
Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
August 10, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson, Chief...
Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, June 23, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European...